This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Referral criteria from primary care - infantile haemangioma (haemangiomas)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Immediate referral of infantile haemangiomas is indicated if (1):

  • active bleeding or clinical compromise (eg, tachycardia, stridor, cardiac murmur, absent femoral pulses)
  • beard distribution infantile haemangiomas and stridor: risk of obstructive airway haemangiomas (requires ear, nose, and throat assessment)
  • uncontrolled pain from ulcerated lesions

There are 5 major indications for consideration of early treatment or need for further evaluation of infantile haemangiomas (IH):

  • 1) life-threatening complications
    • include obstructing IHs of the airway, liver IHs associated with high-output congestive heart failure and severe hypothyroidism, and, rarely, profuse bleeding from an ulcerated IH
      • obstructing IHs of the airway
        • typically involve the subglottis, further compromising the narrowest portion of the pediatric airway
        • although the mean age at the time of diagnosis is about 4 months, symptoms usually present much earlier but are often mistaken as infectious or inflammatory croup or reactive airway disease
        • most children who are affected develop biphasic stridor and barky cough as the IH enlarges
        • segmental IH of the lower face ("beard distribution") or anterior neck and oral and/or pharyngeal mucosal IHs are the greatest risk factors for an airway IH
    • a consumptive form of hypothyroidism caused by the inactivation of thyroid hormones by type 3 iodothyronine deiodinase present in IH tissue can also be a complication of multifocal or diffuse hepatic IH

  • 2) functional impairment or risk thereof
    • examples of functional impairment include visual disturbance and interference with feeding because of IH involvement of the lips or mouth (1,2)
      • periocular infantile haemangiomas; can result in astigmatism, anisometropia (where the refractive error differs between the two eyes), proptosis (bulging or protruding eyeballs), or amblyopia (inability to see clearly through one eye- also known as "lazy eye")
        • specific characteristics that place an infant at a higher risk for amblyopia include an IH size of >1 cm, upper eyelid involvement, associated ptosis, eyelid margin changes, medial location, and segmental morphology or displacement of the globe
      • lip or oral cavity haemangiomas; can result in breathing or feeding difficulties
      • more than five cutaneous haemangiomas; requires prompt further assessment for liver haemangiomas. Large liver haemangiomas can result in cardiac failure or consumptive hypothyroidism (1)

  • 3) ulceration or risk thereof (1,2)
    • skin or mucosal ulceration of the IH surface occurs with an estimated incidence of 5% to 21% in referral populations
    • ulceration can lead to significant pain, bleeding, and secondary infection and virtually always results in scarring
    • ulceration occurs most frequently in infants younger than 4 months, during the period of active IH proliferation
    • IH associated with a high risk of ulceration (1)
      • segmental infantile haemangiomas >5 cm in size
      • haemangiomas of intertriginous sites or areas of frequent friction:
        • lips, columella, superior helix of ear, gluteal cleft, and/or perineum, perianal skin

  • 4) evaluation to identify important associated structural anomalies
    • a small subset of children with IHs have associated congenital anomalies
    • PHACE syndrome (OMIM 606519)
      • Posterior fossa and other structural brain malformations; large haemangiomas of the face, neck, and/or scalp; anomalies of cerebral or cervical
        arteries; cardiac anomalies/coarctation of the aorta; eye abnormalities and sternal clefting or supraumbilical raphe
      • acronym "PHACES" is sometimes used instead to include potential ventral midline defects, specifically sternal cleft and/or supraumbilical raphe (2)
      • crebrovascular anomalies, present in more than 90% of patients with PHACE syndrome, are the most common extracutaneous feature of the syndrome, followed by cardiac anomalies (67%) and structural brain anomalies (52%) (2)
      • risk of PHACE syndrome in an infant presenting with a large segmental IH of the head or neck is approximately 30% (2)
    • LUMBAR syndrome
      • lower body haemangioma, urogenital abnormalities/ulceration, myelopathy, bony deformities, anorectal malformations
      • may best be viewed as the "lower half of the body" equivalent of PHACE syndrome (2)
        • IHs in LUMBAR syndrome are almost invariably segmental, involving the lumbosacral or perineal skin and often extending onto 1 leg

  • 5) risk of leaving permanent scarring or distortion of anatomic landmarks
    • IHs can lead to permanent disfigurement either via scarring of the skin or distortion of anatomic landmarks
    • risk of disfigurement is much higher than the risk of functional or life-threatening consequences
    • measurements refer to infants under 6 months
      • facial infantile haemangiomas: risk of disfigurement via distortion of anatomical landmarks, scarring, or permanent skin changes
      • haemangiomas on nasal tip or lip and those >2 cm at any other facial location (or >1 cm if baby is 3 months or younger)
      • scalp infantile haemangiomas >2 cm: permanent alopecia (especially if the haemangioma becomes thick or bulky); also risk of profuse bleeding if ulcerates (typically more bleeding than at other sites)
      • neck, trunk, or extremity infantile haemangiomas >2 cm, especially if early in growth phase or if there is an abrupt transition from normal to affected skin (ledge effect): Greater risk of leaving permanent skin changes depending on anatomical location
      • breast infantile haemangiomas (female infants): problems with breast development (eg, breast asymmetry) or nipple contour

Reference:

  • Surlis T, De Sa Reilly H, Sadlier M, Nelson J. Infantile haemangiomas BMJ 2022; 378 :e068734 doi:10.1136/bmj-2021-068734
  • Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Greene AK, Annam A, Baker CN, Frommelt PC, Hodak A, Pate BM, Pelletier JL, Sandrock D, Weinberg ST, Whelan MA; SUBCOMMITTEE ON THE MANAGEMENT OF INFANTILE HEMANGIOMAS. Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics. 2019 Jan;143(1):e20183475.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.